Quantitative Advantage’s iShares Biotechnology ETF IBB Stock Holding History

Quantitative Advantage’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-94,626	Closed	-$10.7M	–	49
2015 Q4	$10.7M	Sell	94,626 -2,160	-2%	-$234K	3.04%	9
2015 Q3	$9.79M	Sell	96,786 -3,981	-4%	-$477K	2.76%	9
2015 Q2	$12.4M	Sell	100,767 -1,011	-1%	-$121K	3.19%	9
2015 Q1	$11.7M	Buy	+101,778	New	+$11.2M	2.96%	12

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Quantitative Advantage's IBB Position: Q1 2016 in Review

Quantitative Advantage sold out of iShares Biotechnology ETF (IBB) in Q1 2016, closing a stake of 94,626 shares — an estimated $10.7M sold.

Quantitative Advantage first reported a position in IBB in Q1 2015 and held it in 4 quarters. The position peaked at $12.4M in Q2 2015. 415 funds tracked by Wall St. Rank hold IBB as of Q1 2016.

Quantitative Advantage reported no remaining iShares Biotechnology ETF position as of Q1 2016 after selling out during the quarter.
Quantitative Advantage sold 94,626 iShares Biotechnology ETF shares in Q1 2016, an estimated $10.7M.
Quantitative Advantage first reported a position in iShares Biotechnology ETF in Q1 2015 and held it in 4 quarters.
Quantitative Advantage's iShares Biotechnology ETF position peaked at $12.4M in Q2 2015.
415 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2016.

Based on Quantitative Advantage's 13F filing for Q1 2016, filed 3 May 2016.